{"id": "379742", "url": "https://fevir.net/resources/Evidence/379742", "meta": {"versionId": "5", "lastUpdated": "2025-07-01T19:02:55.589Z"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group", "author": [{"name": "Joanne Dehnbostel"}], "citeAs": "Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group [Database Entry: FHIR Evidence Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 379742. Revised 2025-07-01. Available at: https://fevir.net/resources/Evidence/379742. Computable resource at: https://fevir.net/resources/Evidence/379742#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "relatesTo": [{"type": "part-of", "targetReference": {"type": "Composition", "display": "Outcome Measure Report for QUARTET USA Trial", "reference": "Composition/375280"}}], "statistic": [{"note": [{"text": "The reported percentage (17.2%) does not match the value reported for this outcome in ClinicalTrials.gov results reporting (20% at https://fevir.net/resources/Composition/370504)"}], "quantity": {"code": "%", "unit": "%", "value": 17.24137931034483, "system": "http://unitsofmeasure.org"}, "sampleSize": {"knownDataCount": 29, "numberOfParticipants": 32, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/number-analyzed", "valueUnsignedInt": 29}]}, "statisticType": {"coding": [{"code": "STATO:0000639", "system": "https://fevir.net/sevco", "display": "percentage"}]}, "numberAffected": 5}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "379742", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Evidence", "variableDefinition": [{"observed": {"type": "Group", "display": "QUARTET USA Trial Quadpill group", "reference": "Group/375175"}, "variableRole": "population"}, {"observed": {"type": "EvidenceVariable", "display": "Adverse event free and hypertension control at 12 weeks", "reference": "EvidenceVariable/375278"}, "variableRole": "outcome"}], "name": "Evidence_for_Results_for_Adverse_event_free_and_hypertension_control_at_12_weeks_in_QUARTET_USA_Trial_Quadpill_group", "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}